MAP2K7 and melanoma: The leading molecular biomarker in the context of a targeted therapy in patients with melanoma is the presence of the BRAFV600 mutation, as the role of BRAF/MEK inhibitors is well established in adjuvant or palliative therapy in patients with BRAF-mutated tumors [7,8,58].